All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 2 days ‐ immediate treatment (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
1 finding from 1 review
Mortality: in‐hospital mortality (time points varied) · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: in‐hospital mortality (time points varied) compared with standard practice storage duration (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).
1 finding from 1 review
Mortality: short‐term mortality (up to 30 days) ‐ adults · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: short‐term mortality (up to 30 days) ‐ adults compared with standard practice storage duration (moderate certainty).
1 finding from 1 review
Mortality: short‐term mortality (up to 30 days) ‐ neonates · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: short‐term mortality (up to 30 days) ‐ neonates compared with standard practice storage duration (very low certainty).
1 finding from 1 review
Intervention not reported
Clinical outcome: all‐cause mortality ATCS Plus versus usual care or usual community care at median · patients with heart failure
The intervention showed no clear difference in clinical outcome: all‐cause mortality ATCS Plus versus usual care or… (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical outcome: cardiac mortality ATCS Plus, IVR versus usual care or usual community care at median · patients with heart failure
It is very uncertain whether the intervention changes clinical outcome: cardiac mortality ATCS Plus, IVR versus usual care… (very low certainty).
1 finding from 1 review
All‐cause mortality Time point of measurement: 2 months in 1 randomised study; 12 months in 3 randomised studies; 14 months in 1 non‐randomised study · adult survivors of the ICU, excluding those already in an existing follow‐up or rehabilitation programme
1 finding from 1 review